The endgame for serogroup a meningococcal disease in Africa?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Impact of MenAfriVac on Meningococcal A Meningitis in Cameroon: A Retrospective Study Using Case-by-Case-Based Surveillance Data from 2009 to 2015.Journal of tropical medicine · 2021
   Article
2. DNA Methylation Assessed by SMRT Sequencing Is Linked to Mutations in Neisseria meningitidis Isolates.PloS one · 2015
   Article
3. Editorial commentary: fifteen years of protection by meningococcal C conjugate vaccines: lessons from disease surveillance.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014
   Article
4. The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2013
   Review

Corrections and comments

• Comment on
  Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.2013

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as